Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree that most of TRXC PR is garbage, but it has contributed to them being able to maintain a pps through thick and thin.
This could have also been done at Titan (we begged for it), but we've always had a crew that's been a bit to "righteous". You might commend them on that account, but there is something to be said for:
Gamesmanship - the art of winning games by using various ploys and tactics to gain a psychological advantage
Titan has NEVER had it. Unfortunately, for us.
Oopps disregard that.
How quickly after FDA approval do you think this would take if they chose to go this route? I assume they cannot solicit pre-orders until the unit is actually FDA approved.
The smart strategy would be to bring in decision makers from key institutions from around the country and secure pre-orders to generate sales. This can be done way ahead of launch and it looks great for companies interested in acquiring titan.
But do you think they will go that far with SPORT before a buyout? Will they go at alone for a short time to generate sales figures then entertain a buyout?
Looks like these type of deals would open up a lot of possibilities for Titan
Somebody recently posted a link to an article about tech company buyouts, and this type of phased buyout was one of the models they presented in the article.
RACKO TITAN/VERB/ETHICON
I couldn’t agreed more!
1.1 billion.....
When you think of the potential revenue that SPORT could generate as well as other tie-ins that a large med device company could piggyback off of SPORT, billions seems realistic....
Nice find thanks for the post!
Interesting. Thanks for sharing.
I am hoping that all the doctors at the clinical sites are working SPORT like Harvey Weinstein works a bar of Dove soap!
Teleflex buys Neotract (51m in sales)
for 1.1 billion in a phased acquisition. I think Titan enters into a phased partnership or acquisition in the future. Seems like a way for a company to buy another at an earlier stage than they traditionally would have. Portion of the payment is tied to sales milestones to 2020.
Just my 2c.
http://www.massdevice.com/teleflex-closes-1b-neotract-buy/
That is great news! And yes that has to be going on around the country. Lots of buying going on these past several weeks.
I am a believer in news, does not have to be "fluff" per se, but even small updates keeps investors in the know and salivating for more. I agree a nice base building here at .25 is solid for our next push higher.
Cannot wait for that first round! ;)
I knew there was good people on this forum...
Mc won't release news just to have news out there. Not a believer in fluff pieces. Only wants something significant and news worthy to Titan. Personally I can see the argument for both. I don't mind seeing mundane Titan news. Regardless, we do need some catalyst to get us to the next level. Although a nice base here at .25 isn't the worse thing.
Unrelated note... talked to my local Scottrade rep to facilitate a non-Titan trade. She mentioned that she's receives a few calls in the past couple weeks about Titan and everyone is buying. She said one is a local surgeon who has been hearing about how good it is so he decided to buy as well. If this is a trend around the country, it bodes well for the stock.
I guess it turns out to be a related note after all... News would keep us in the spotlight and keep these private buys rolling, which keeps PPS moving the right direction. I must agree that today's volume isn't what we have become accustomed to seeing lately.
Need news!
Even relatively mundane releases keep a company in somewhat of a spotlight. Look at TRXC... They announced their 100th case for that European Senhance system they sold. And they made it sound good by not pointing out that 100 cases in 8 months is not a viable business model for a hospital (12 per month or 3 per week). Yet they tripled their stock price in the last 5 months, not by being silent about what they are doing, but by presenting unimportant information or even info with negative connotations as being positive. Oh yeah, don't forget "We replied to the FDA's AI (Additional Information) request in less time than anticipated!" Wow, awesome news... which overlooks the fact that their initial submission was incomplete or insufficient, which is why the FDA needs the AI to begin with. For a company that just went through multiple submissions only to get completely shot down in April 2016, one would think they would get their act together and nail things down first pass this time. Nope, they screwed the pooch again, and somehow present it in a positive light in their PR, and get another bump up in PPS. It's all in the spin!
Why can't we do that?
In the absence of more news we have greatly slowed down today regarding our trading volume and push higher as many of us anticipated. I am glad to see there has not been a raise announced yet, as many predicted may happen last week or this week. I'm hopeful for further feedback this week or next from Nicholson/surgeons, or an unexpected pleasant surprise from Mac and team to help us break into the 30s and higher, where a raise would be a lot more beneficial to all. We shall see...
Nice. I hate everything about the way you choose to be. My wife and I border on absurdity with our office quoting. Probably seen the whole series at least 20x its what we usually watch during dinner..
Cool. I'm in Wading River. A little slow for my taste but good schools and safe for my kids.
If I was at a cocktail party I would say yes, Fletcher Henderson, but I'm not quite that refined. Toby Flenderson was a character from the T.V. show "The Office".
Like...Hey Mustang you always bring something new to the table.
The Flag is "USA" and it deserves respect, and while I feel bad for mistreatments and such I also believe it should be done at a different platform than sitting for the National Anthem. It's a phenomenon. Hey if you call Budweiser (a big advertiser) to complain their first option is about NFL complaints...
Kids tuition - Farmingdale - but my plan is to retire in the North Fork area (about 5 years unless Titan makes me rich sooner). Member of Laurel Lakes vineyard - good wine, place. I prefer Scotch
Where in Long Island? I'm on the North Fork
Well, since the Red Sox are out of it, I can wish you good luck tonight! Never was much of a Yankees fan myself, but I turned some heads in this area back in the day when I'd say that Jeter would have looked great in a Red Sox uniform. Class act on and off the field. If I was ever rooting for the Yankees, I was really only rooting for Jeter - and never if it jeopardized the Sox' standings.
Pats fan too, but also a veteran. I felt it wasn't fair to suggest we boycott the NFL because New Englanders would be giving up something a bit more special than most areas, but once McCourty took a knee... Well, they aren't doing so great so far anyway. And MLB Player's Association came out in support of player protests. I found it rather ironic that MLB consists of the American League and the National League, but they are protesting the American Flag and the National Anthem. If they are protesting against police brutality, they should march in front of a police station. They devalue their argument by turning it into a media circus while raking in millions of dollars and claiming they don't get a fair chance.
If I get millions of dollars from Titan stock (fingers crossed, but it looks good!) I don't expect to be complaining about it like the sports stars.
You and Rebster must be thankful NE Pats and Red Sox fans. As a Long Islander "Lets go Yanks" tonight and Titan thereafter. A little concerned with Sabathia but hopefully the Judge breaks out, not hitting home runs but catching them!
One other quick question for Flenderson...
Is the name Flenderson meant a tribute to 1920's orchestra leader Fletcher Henderson? Or just coincidental?
Flenderson, I look forward to meeting you in person! It was rather insightful for you to pick up on Rebster's Manchester roots.
Sounds good. Hopefully Titan will not disappoint!
I'm in CA. My wife is from Nashua. Ironically enough her cousins are Boucher's living in Milford. Of course that's like Smith anywhere else. We'll be out next summer. Hope I can meet you and 66 at the pub and discuss craft beer and Titan. For the record, I'm guessing Titan is at $1.50+ by then...
Tee off at 9AM? The party should just be winding down!
We had better have some damn strong Bloody Marys in the limo ride to the golf course!
I didn’t see that. I think we go it alone...FYI.
20,- and I'm good till 99 yrs old.
10,- and I'm good till 85 yrs gold.
I'd take 20,- :)
Yes sir, still live there today and the last name is Boucher. ( got a major shout out in the Waterboy.). Believe it or not I live about 5 miles from Mustang66 and have met with him numerous times at the local pub to have him school me in all things Titan, ( and Craft beer!)
Sheeet I'd be happy with .58 and a break even
You must be from Manchester...
The current optimism has nothing to do with those comments. It is due to the fact that we now have evidence that Titan has a working robot. This is no longer Uncle Dennis' science project. The robot did what it was expected to do under simulated operative conditions. It seems that if any tweaks are needed, they will be minor.
We don't eat baloney on this board so sounds like to me you need to go to another board. We drink scotch, smoke high end cigars and tee off at 9 am. You're on the wrong board.
Your scenario is a "going at it alone" to begin with then being bought out. I think the original scenario was assuming we weren't going at it alone and McNally and Co. were going to unload this as soon as FDA approval happens. If we wait and put the for sale sign up after we've made sales then sure. We could get to that number. But IMO, that's not the plan.
If I had a couple slices of bread I could make a baloney sandwich after listening to all these 5,10 and even 20 dollars buyouts. In reality there has only been one gyn surgeon who owns a lot of titan stock. who said it was a game changer. Patel et al were not as demonstrative Until we get a lot of more positive comments about titans role in robotic surgery from people who are not connected to titan in some way Only then will I become a dreamer like the rest of you
Why is that unrealistic? It’s an 8 billion evaluation. With the rate companies are selling these days, anything is possible. If they generate sales and then sell, we could easily hit this number
I am hoping for $12.33 so I can buy a house next my childhood friend Adam Sandler in the Hollywood hills!
If we get $20/share and that isn't counting in a R/S I will turn in my resignation immediately. LOL! I'm afraid $20/share buyout is a bit unrealistic. But I hope you're right.
My minimum is 20. I need to get paid that I can retire now, if I wanted to
The fact that Titan has not pulled the trigger on a new financing at these levels is VERY positive...IMO Money from warrants is allowing them a little more time and flexibility. Mc wants pps as high as possible before there next move. They will be "picking the best offer presented to them."
Don't think I would want to be short, or selling now with 2nd and 3rd site details coming soon.
GLTA
Titan Medical
January 10, 2022 Titan Medical Corporate Presentation
https://d1io3yog0oux5.cloudfront.net/_101e2d94c73b26bc133246c537736f29/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+Q1+2022+FINAL.pdf
*200+ patents issued or pending
Surgeon Feedback From Initial Clinical Testing:
Ricardo Estape, M.D., a robotic gynecologic oncology surgeon from South Miami Gynecology Oncology Group who specializes in robotic single port surgeries, said, “The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.” SEE VIDEO
Eduardo Parra-Davila, M.D., a robotic colorectal surgeon at Florida Hospital who has trained thousands of surgeons worldwide on robotic surgery, commented, “Single port surgery without robotic assistance is not easy and yet it remains highly beneficial because of the desire to have fewer ports. It’s all about robotic articulation delivered through a single incision that allows for the reach, necessary angles and multi-quadrant access to treat diseases in colorectal surgeries. The SPORT Surgical System has the promise to become a valuable tool for all robotic surgeons looking to do single port surgery in the future.” SEE VIDEO
Arnold Advincula, M.D., Chief of Gynecologic Specialty Surgery at Columbia University and an expert in robotic surgery, said, “After using the SPORT system, I am more convinced that single-port robotic surgery could become a reality for many patients. Previous approaches to single-incision surgery have been limiting and ineffective. The SPORT system demonstrated that it can not only address those limitations, but it may also provide some unique capabilities for enabling a variety of gynecologic surgeries through a single incision. The future of single-port robotic surgery is bright and I am excited to actively participate in this journey with Titan Medical.”
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
William Burke, M.D., a gynecologic oncologist at Stony Brook University Hospital with extensive robotic surgery experience, commented, “Having completed thousands of multi-port robotic surgeries over several years of practice, I was pleased with the capabilities of the SPORT system that eased my transition from a multi-port approach to single-port robotic surgery. The workspace, access and ease of use while maintaining critical multi-port robotic features such as multi-articulated instruments and high-definition 3D visualization through a single incision, are important factors in transitioning from multi-port to single-port robotic surgery. I must say that the SPORT system, with its sophistication, makes a highly compelling case for single-port robotic surgery.”
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
Jelle Ruurda, MD, a gastrointestinal and oncologic surgeon at University Medical Center Utrecht, who has several years of robotic surgery experience, commented, “Many oncologic general surgery procedures require specimen retrieval at the end of the procedure. These procedures are natural applications for single-port robotic surgery. My first operation of the SPORT system in a preclinical environment was very exciting, and the system shows great promise for future clinical use. I look forward to the opportunity to work together with Titan Medical to evolve a single-port robotic surgery option for my oncology patients. Based on this first experience, I am confident that single-port robotic surgery has a bright future”.
Eric Barret, MD, a world-renowned robotic urologic surgeon at Institut Mutualiste Montsouris, said, “Having performed many single-incision robotic surgeries with flexible, non-wristed and crossed-over instruments, my first experience with the SPORT system was exceptional. The SPORT system addresses many limitations of previous laparoscopic and robotic single-incision surgery approaches, and holds significant promise for meaningful use in urologic applications.”
The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation. http://www.titanmedicalinc.com/
Interim President & CEO
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility. Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors. He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.
Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.
Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.
Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.
Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |